In vitro induction of dopaminergic cells

• US 5,981,165 A
• Filed: 06/07/1995
• Issued: 11/09/1999
• Est. Priority Date: 07/08/1991
• Status: Expired due to Fees

• Current Assignee: Neurospheres Holding Limited
• Original Assignee: Neurospheres Holding Limited
• Inventors: Weiss, Samuel, Reynolds, Brent
• Primary Examiner(s): Degen, Nancy
• Assistant Examiner(s): SANDALS, WILLIAM O
• Application Number:
  US08/482,079
• Time in Patent Office: 1,616 Days
• Field of Search: 424/92 R, 424/93.7, 435/1, 435/240.2, 435/4, 435/325, 514/2, 530/399
• US Class Current: 435/4
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/30 Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 14/475 Growth factors; Growth regulators
• CPC Class Codes: C07K 14/82 Translation products from oncogenes
• CPC Class Codes: C12N 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
• CPC Class Codes: C12N 2500/90 Serum-free medium, which may still contain naturally-sourced components
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/148 Transforming growth factor alpha [TGF-a]
• CPC Class Codes: C12N 2501/155 Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
• CPC Class Codes: C12N 2501/16 Activin; Inhibin; Mullerian inhibiting substance
• CPC Class Codes: C12N 2502/08 cells of the nervous system
• CPC Class Codes: C12N 2510/00 Genetically modified cells
• CPC Class Codes: C12N 5/0618 Cells of the nervous system
• CPC Class Codes: C12N 5/0619 Neurons
• CPC Class Codes: C12N 5/0623 : Stem cells
• CPC Class Codes: C12N 5/0676 : Pancreatic cells
• CPC Class Codes: C12N 9/0071 : acting on paired donors with incorporation of molecular oxygen (1.14)
• CPC Class Codes: C12Y 114/16002 : Tyrosine 3-monooxygenase (1.14.16.2)

Abstract

A culture method for inducing the expression of tyrosine hydroxylase in neural cells is provided. Mammalian CNS neural cells are cultured in the presence of a fibroblast growth factor and at least one selected from a member of the transforming growth factor beta family, a feeder layer bed of cells, and cell conditioned medium. Cells cultured as provided above may be transplanted to provide dopaminergic cells to a patient. The cells may also be used in methods for drug screening.

Claims

1. A method for inducing the expression of tyrosine hydroxylase in neural cells in vitro comprising culturing mammalian CNS neural cells derived from normally non-dopaminergic, non-tumorigenic tissue in a culture medium to which has been added at least one member of the fibroblast growth factor family and at least one member of the transforming growth factor beta family wherein tyrosine hydroxylase is expressed.

2. The method of claim 1 wherein said culture medium is defined, said member of the fibroblast growth factory family is FGF-2 and said culture medium comprises a member of the transforming growth factor beta family selected from the group consisting of activin and bone morphogenic protein-2.

3. The method of claim 1 wherein said normally non-dopaminergic tissue is neural tissue selected from the group consisting of the striatum and the cortex.

4. The method of claim 1 wherein said culture medium further comprises serum.

5. The method of claim 1 wherein said neural cells are cultured in the absence of a feeder layer.

6. The method of claim 1 wherein said neural cells are primary cells obtained from embryonic tissue.

7. The method of claim 1 wherein said culture medium is defined.

8. The method of claim 1 wherein said neural cells are cultured on an ionically charged surface selected from the group consisting of poly-D-lysine, poly-L-ornithine, MATRIGEL™

, laminin, and fibronectin.

9. The method of claim 8 wherein said charged surface is poly-L-ornithine.

10. The method of claim 1 wherein said neural cells are the progeny of at least one multipotent neural stem cell which was induced to proliferate in vitro by the presence of one or more growth factors.

11. The method of claim 10 wherein said multipotent neural stem cell is derived from juvenile or adult neural tissue.

12. The method of claim 1 wherein said neural cells are primary cells.

13. The method of claim 12 wherein said member of the fibroblast growth factor family is FGF-2 and said member of the transforming growth factor beta family is selected from the group consisting of activin and bone morphogenic protein-2.

21. A cell culture comprising tyrosine-hydroxylase-expressing cells prepared by the method of claim 1.

22. The cell culture of claim 21, wherein said culture medium is defined, said member of the fibroblast growth factor family is FGF-2 and said member of the transforming growth factor beta family is selected from the group consisting of activin and bone morphogenic protein-2.

23. The cell culture of claim 21 which is cultured on an ionically charged surface selected from the group consisting of poly-D-lysine, poly-L-ornithine, MATRIGEL™

, laminin, and fibronectin.

24. The cell culture of claim 21 wherein said normally non-dopaminergic CNS tissue is selected from the group consisting of the striatum and the cortex.

25. The cell culture of claim 21 wherein said culture medium further comprises conditioned medium selected from the group consisting of astrocyte conditioned medium and glial cell conditioned medium.

26. The cell culture of claim 21 wherein said neural cells are the progeny of at least one multipotent neural stem cell proliferated in vitro in the presence of one or more growth factors which induced proliferation of said at least one multipotent neural stem cell.

27. The cell culture of claim 26 wherein said multipotent neural stem cell is derived from adult neural tissue.

28. The method of claim 1 wherein said culture medium further comprises at least one member selected from the group consisting of a feeder layer bed of cells and cell conditioned medium.

29. The method of claim 28 wherein said member of the fibroblast growth factor family is FGF-2 and said member of the transforming growth factor beta family is selected from the group consisting of activin and bone morphogenic protein-2.

30. The method of claim 28 wherein said culture medium comprises cell conditioned medium selected from the group consisting of astrocyte conditioned medium and glial cell conditioned medium.

31. The method of claim 30 wherein said cell conditioned medium is derived from rat B49 glial cell line.

14. A method of providing dopaminergic cells to a patient comprising transplanting neural cells which are mammalian CNS neural cells derived from normally non-dopaminergic, non-tumorigenic tissue in a culture medium to which has been added at least one member of the fibroblast growth factor family and at least one member of the transforming growth factor beta family to induce the expression of tyrosine hydroxylase in said neural cells into said patient'"'"'s CNS.

15. The method of claim 14 wherein said patient has Parkinson'"'"'s disease and said neural cells are administered to said patient'"'"'s striatum.

16. The method of claim 14 wherein said member of the fibroblast growth factor family is FGF-2 and said member of the transforming growth factor beta family is selected from the group consisting of activin and bone morphogenic protein.

17. The method of claim 14 wherein said culture medium is defined.

18. The method of claim 14 wherein said neural cells are obtained from the CNS of said patient.

19. A method of screening the effects of a drug on dopaminergic cells comprising culturing mammalian CNS neural cells derived from normally non-dopaminergic, non-tumorigenic tissue in a culture medium to which has been added at least one member of the fibroblast growth factor family and at least one member of the transforming growth factor beta family to induce the expression of tyrosine hydroxylase in said neural cells contacting said neural cells with a drug and measuring the response, selected from the group consisting of a dopaminergic response and cell survival, of said dopaminergic cells to said drug.

20. The method of claim 19 wherein said effects are determined by measuring the ability of said cells to produce or metabolize dopamine.

32. A method for inducing the expression of tyrosine hydroxylase in neural cells in vitro comprising preparing a cell culture comprising mammalian CNS neural cells derived from normally non-dopaminergic neural tissue and a culture medium to which has been added at least one member of the fibroblast growth factor family and wherein said culture medium additionally comprises a member selected from the group consisting of a feeder layer bed of cells, cell conditioned medium, and members of the TGFβ

family to induce the expression of tyrosine hydroxylase in said neural cells.

33. The method of claim 32 wherein said culture medium further comprises serum.

34. The method of claim 32 wherein said neural cells are the progeny of at least one multipotent neural stem cell proliferated in vitro in the presence of one or more growth factors which induced proliferation of said at least one multipotent neural stem cell.

35. The method of claim 32 wherein said normally non-dopaminergic tissue is selected from the group consisting of the striatum and the cortex.

36. The method of claim 32 wherein said culture medium comprises a feeder layer bed derived from normally non-dopaminergic neural tissue.

37. The method of claim 36 wherein said culture medium further comprises serum.

38. The method of claim 32 wherein said culture medium comprises cell conditioned medium.

39. The method of claim 38 wherein said cell conditioned medium is derived from glial cells.

40. The method of claim 38 wherein said cell conditioned medium is derived from astrocytes.

41. The method of claim 38 wherein said cell conditioned medium is derived from rat B49 glial cell line.